Celebrex returns to TV with long, blunt spot

Share this article:
Pfizer resumed DTC television advertising for Celebrex on Monday with a whopping 150-second spot that takes up an entire commercial break. Turning conventions of traditional prescription drug TV spots upside down, the spot, created by Kaplan Thaler, presents its warning information first – noting that Celebrex, and rivals ibuprofen and naproxen, all may cause heart attack, stroke and death. Celebrex’s benefits are stated afterward. The two-and-a-half-minute Celebrex spot uses blue and white lines composed of words from the package inserts of Pfizer painkiller and other drugs to create animations of people running, dancing and riding a bicycle. Pfizer spokesman Jack Cox told MM&M the ad will appear on network and cable television with a print complement to appear in national publications such as Time and US News and World Report. The ad also appears on the product’s Web site at Celebrex.com. Each commercial may cost more than $200,000 to air. Pfizer yanked television advertising for Celebrex in the wake of the 2004 withdrawal of Merck’s Vioxx. An FDA panel later said that painkillers similar to Vioxx, known as COX- 2 inhibitors, also carried the same risks of heart attack and stroke. As a result, Pfizer withdrew its COX-2 Bextra from the market in April 2005. Celebrex, however, remains available to consumers. Even without a major TV ad campaign behind the brand, global sales of Celebrex jumped 18% in 2006, exceeding $2 billion.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.